ArticleBMJ neurology open2026
Effect of deep brain stimulation on patients with Parkinson's disease with mild cognitive impairment.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive deficits are prevalent in Parkinson's disease (PD), often progressing to PD dementia (PDD). Deep brain stimulation (DBS) is an established treatment for PD motor symptoms, but its effects on patients with mild cognitive impairment (PD-MCI) remain unclear. While MCI is a relative contraindication for DBS, evidence regarding its impact on post-operative outcomes is limited. This systematic review aims to assess the post-operative cognitive and functional outcomes of DBS in patients with PD and MCI. Methods: A comprehensive literature search was conducted across PubMed, Scopus, PsycInfo and Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies published by February 2024 that evaluated DBS outcomes in patients with PD-MCI were included. Data extraction focused on cognitive assessments, quality of life and clinical outcomes. Results: Eight studies comprising 984 patients met inclusion criteria. Six studies identified PD-MCI as a potential risk factor for developing PDD post-DBS, though only two demonstrated statistically significant cognitive decline post-DBS. Five studies found no differences in outcomes post-DBS, between patients with PD-MCI and PD without cognitive impairment. Conclusions: DBS does not appear to significantly worsen cognitive decline in patients with PD-MCI beyond the expected disease progression. However, certain cognitive domains, particularly visuospatial impairments, may increase the risk of adverse outcomes. Standardised cognitive screening is necessary for optimal patient selection for future research to refine clinical guidelines for DBS eligibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.